STAT3 and nonpapillary renal cell carcinoma: It is well known that sunitinib inhibits the phosphorylation of STAT3 in cells.[42, 43] Similarly, we revealed that sunitinib, axitinib, and lenvatinib treatment suppressed the phosphorylation of STAT3 and increased the expression of HDAC8 in ccRCC cells (Figure 7I–K).